Nov. 17, 2025 — GE HealthCare has announced that Cardiovascular Associates of America (CVAUSA) plans to broaden its adoption of GE HealthCare’s FDA-approved cardiac positron emission tomography (PET) ...
Radiopharmaceuticals and Tracers
This channel includes news and new technology innovations for nuclear and molecular imaging agents, radiotracers and radiopharmaceuticals used in PET or SPECT imaging. This includes advances in myocardiac perfusion agents.
-
-
April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T ...
-
April 7. 2024 — A single subcutaneous injection of the investigational drug zilebesiran, when added to existing treatment with a standard antihypertensive medication, reduced systolic blood pressure ...
-
April 7, 2024 — An estimated 1 in 5 U.S. adults—and more than 2 in 5 adults aged 60 years and older—have elevated triglycerides, also known as hypertriglyceridemia, putting them at an increased risk ...
Nov. 17, 2025 — GE HealthCare has announced that Cardiovascular Associates of America (CVAUSA) plans to broaden its ...
November 17, 2025
Sept. 8, 2025 — GE HealthCare recently announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of ...
September 08, 2025
March 27, 2025 — GE HealthCare is announcing the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the 2025 ...
March 25, 2025
June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac ...
June 11, 2024
April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...
April 09, 2024
April 7. 2024 — A single subcutaneous injection of the investigational drug zilebesiran, when added to existing ...
April 07, 2024
April 7, 2024 — An estimated 1 in 5 U.S. adults—and more than 2 in 5 adults aged 60 years and older—have elevated ...
April 07, 2024
April 13, 2023 — A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin ...
April 13, 2023
Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...
November 05, 2022![Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD)](/sites/default/files/styles/content_feed_medium/public/Screen%20Shot%202022-09-13%20at%203.30.13%20PM.png?itok=2w6OoNd6)
September 14, 2022 — GE Healthcare and Lantheus Holdings Inc have announced that the recent Phase III clinical trial of ...
September 14, 2022
June 24, 2022 — Shortages of pyrophosphate (PYP), the radiopharmaceutical most commonly used in the U.S. for noninvasive ...
June 24, 2022
April 29, 2022 — Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Camzyos ...
April 29, 2022
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at ...
November 22, 2021
As hospital imaging departments look to replace aging nuclear scanners with updated technology, many are asking if ...
February 19, 2020
Feature | Nuclear Imaging | Dave Fornell, Editor
There were a few key takeaways from the American Society of Nuclear Cardiology (ASNC) 2019 annual meeting in September ...
November 22, 2019© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now